- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02361450
Retrograde Colonic Irrigation to Manage Spina Bifida Functional Digestive Sequelae: a Multicenter, Prospective, Randomized Controlled Trial (IRRICO)
Spina Bifida is a developmental congenital disorder caused by the incomplete closing of the embryonic neural tube, leading to serious malformations of the nervous system. Caudal neuropore malformations almost always lead to sensory-motor deficits (including complete paraplegia) with orthopedic deformations, pressure sores, and pelvic/perineal neurological dysfunctions (affecting the bladder-sphincter, anorectal, and genital sphere).
The purpose of the study is to assess the efficacy of retrograde colonic irrigation associated with usual care (medical treatments, patient education) on anorectal dysfunction (incontinence and/or constipation), compared to usual care only.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sphincter dysfunctions impair the quality of life and patients' self-esteem. However, defecation disorders are important issues the Spina Bifida National Reference Center has to deal with. Indeed, more than half of patients are concerned. These disorders are mainly due to fecal stasis. Treatments include laxatives and hygiene recommendations. Colonic irrigation can also be useful, especially to achieve colonic vacuity and improve continence. The use of intra-rectal balloon inflation probes and the control of instillation flow improved retrograde colonic irrigation efficacy. Nevertheless, this technique is currently not evaluated in young adults suffering from Spina Bifida functional digestive sequelae, who are mainly concerned by Malone enema.
The purpose of the study is to assess the efficacy of retrograde colonic irrigation associated with usual care (medical treatments, patient education) on anorectal dysfunction (incontinence and/or constipation), compared to usual care only.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lille, France, 59037
- CHRU de Lille
-
Nantes, France, 44093
- CHU de Nantes
-
Ploemeur, France, 56275
- CMRRF de Kerpape
-
Rennes, France, 35000
- Rennes University Hospital
-
Rouen, France, 76031
- CHU de Rouen
-
Vandoeuvre les Nancy, France, 54511
- CHRU de Nancy-Brabois
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aging at least 15 years old with Spina Bifida neurological pelvi-perineal sequelae, objected by neurologic exam , functional urinary and/or anorectal and/or neurophysiological data,
- Patients with NBD score above 9,
- Written and informed consent (Minor children may be included with the consent of the two parents).
Exclusion Criteria:
- Patients with psychiatric disorders, cognitive or intellectual disabilities compromising the assessment of primary outcome measure,
- Patients using currently irrigation colonic technique,
- Patients with functional colostomy, known anal or colorectal stenosis, colorectal cancer, acute or chronic inflammatory disease, recent anal or colorectal surgery for less than 3 months, polyp removal for less than 4 weeks, ischemic colitis.
- Patients with urinary trophic or orthopedic disease with planned surgery during inclusion or follow-up periods,
- Patients with progressive anal disease (suppuration, hemorrhoid or rectal prolapse)
- Patient with a hard follow-up ( judged by the investigator)
- Person involved in another clinical trial
- Pregnant women
- Person with a measure of legal protection (guardianship)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Retrograde Colonic Irrigation with usual care
In the experimental group, retrograde colonic irrigation sessions will be scheduled in addition to conventional treatment according to a progressive volume program.
|
|
Active Comparator: Usual Care
In the comparator group, patients will receive conventional care, according to each clinical center habits.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Neurogenic Bowel Dysfunction (NBD) score
Time Frame: Ten weeks after inclusion
|
Ten weeks after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Questionnaire data of incontinence and constipation (Cleveland scores)
Time Frame: Ten weeks after inclusion
|
Ten weeks after inclusion
|
|
Questionnaire data of incontinence and constipation (Cleveland scores)
Time Frame: Twenty-four weeks after inclusion
|
Twenty-four weeks after inclusion
|
|
Quality of life
Time Frame: Ten weeks after inclusion
|
Quality of life will be assess by semi-quantified scales
|
Ten weeks after inclusion
|
Quality of life
Time Frame: Twenty-four weeks after inclusion
|
Quality of life will be assess by semi-quantified scales
|
Twenty-four weeks after inclusion
|
Self esteem (Rosenberg scale)
Time Frame: Ten weeks after inclusion
|
Ten weeks after inclusion
|
|
Functional digestive score (NBD)
Time Frame: Twenty-four weeks after inclusion
|
Twenty-four weeks after inclusion
|
|
Cumulative time spent using restrooms
Time Frame: Ten weeks after inclusion
|
Cumulative time spent using restrooms will be collected with a patient reported outcome questionnaire
|
Ten weeks after inclusion
|
Cumulative time spent using restrooms
Time Frame: Twenty-four weeks after inclusion
|
Cumulative time spent using restrooms will be collected with a patient reported outcome questionnaire
|
Twenty-four weeks after inclusion
|
Number of accidents of incontinence
Time Frame: Ten weeks after inclusion
|
Number of accidents of incontinence will be collected with a patient reported outcome questionnaire
|
Ten weeks after inclusion
|
Number of accidents of incontinence
Time Frame: Twenty-four weeks after inclusion
|
Number of accidents of incontinence will be collected with a patient reported outcome questionnaire
|
Twenty-four weeks after inclusion
|
Number of incontinence guards used
Time Frame: Ten weeks after inclusion
|
Number of incontinence guards used will be collected with a patient reported outcome questionnaire
|
Ten weeks after inclusion
|
Number of incontinence guards used
Time Frame: Twenty-four weeks after inclusion
|
Number of incontinence guards used will be collected with a patient reported outcome questionnaire
|
Twenty-four weeks after inclusion
|
Type of incontinence guards used
Time Frame: Ten weeks after inclusion
|
Type of incontinence guards (panty liner, pad, nappy) used will be collected with a patient reported outcome questionnaire
|
Ten weeks after inclusion
|
Type of incontinence guards used
Time Frame: Twenty-four weeks after inclusion
|
Type of incontinence guards (panty liner, pad, nappy) used will be collected with a patient reported outcome questionnaire
|
Twenty-four weeks after inclusion
|
Number of stools
Time Frame: Ten weeks after inclusion
|
Number of stools will be collected with a patient reported outcome questionnaire
|
Ten weeks after inclusion
|
Number of stools
Time Frame: Twenty-four weeks after inclusion
|
Number of stools will be collected with a patient reported outcome questionnaire
|
Twenty-four weeks after inclusion
|
Stools consistency
Time Frame: Ten weeks after inclusion
|
Stools consistency will be collected with a patient reported outcome questionnaire
|
Ten weeks after inclusion
|
Stools consistency
Time Frame: Twenty-four weeks after inclusion
|
Stools consistency will be collected with a patient reported outcome questionnaire
|
Twenty-four weeks after inclusion
|
Symptoms experienced during defecation
Time Frame: Ten weeks after inclusion
|
Symptoms experienced during defecation will be collected with a patient reported outcome questionnaire
|
Ten weeks after inclusion
|
Symptoms experienced during defecation
Time Frame: Twenty-four weeks after inclusion
|
Symptoms experienced during defecation will be collected with a patient reported outcome questionnaire
|
Twenty-four weeks after inclusion
|
Frequency of digital help during defecation
Time Frame: Ten weeks after inclusion
|
The frequency of digital stimulation will be collected with a patient reported outcome questionnaire
|
Ten weeks after inclusion
|
Frequency of digital help during defecation
Time Frame: Twenty-four weeks after inclusion
|
The frequency of digital stimulation will be collected with a patient reported outcome questionnaire
|
Twenty-four weeks after inclusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Laurent Siproudhis, Md, PhD, Rennes University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-A01520-45
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spina Bifida
-
Medicina Perinatal Alta Especialidad, MéxicoUniversidad de MonterreyUnknown
-
The University of Texas Health Science Center,...RecruitingCryopreserved Human Umbilical Cord as a Meningeal Patch in Fetoscopic Spina Bifida Repair (HUC-FICS)Myelomeningocele | Myeloschisis | Spina Bifida; FetusUnited States
-
Yuzuncu Yıl UniversityCompletedMeningomyelocele/Spina BifidaTurkey
-
The Affiliated Hospital of Putian UniversityCompletedThoracolumbar; Spina Bifida
-
Hospital Israelita Albert EinsteinCompletedChiari Malformation Type 2 | Myelomeningocele | Meningomyelocele | Open Spina Bifida | Chiari Malformation With Spina BifidaBrazil
-
Universitaire Ziekenhuizen KU LeuvenCompletedSpinal Dysraphism | Chiari Malformation Type 2 | Fetal AnomalyBelgium
-
University of Southern CaliforniaUSFetusRecruitingNeural Tube Defects | Myelomeningocele | Spina BifidaUnited States
-
Weill Medical College of Cornell UniversityRecruitingTethered Cord Syndrome | Tethered Cord | Spina Bifida Occulta | Occult Spina BifidaUnited States
-
Mayo ClinicActive, not recruitingNeural Tube Defects | Myelomeningocele | Spina BifidaUnited States
-
University of St. Augustine for Health SciencesCompletedSpina Bifida With HydrocephalusUnited States
Clinical Trials on Usual Care
-
Charite University, Berlin, GermanyCompletedMultiple Sclerosis | FatigueGermany
-
Centers for Disease Control and PreventionCompleted
-
Charite University, Berlin, GermanyMammazentrum Hamburg am Krankenhaus Jerusalem, Germany; Dorit und Alexander...Completed
-
European Institute for Evidence Based Osteopathic...Unknown
-
Suzanna ZickUniversity of MichiganTerminatedQuality of Life | Fatigue | Lupus Erythematosus, Systemic | Sleep | Pain, ChronicUnited States
-
The Miriam HospitalNational Institute on Aging (NIA)RecruitingHeart FailureUnited States
-
Lawson Health Research InstituteUnknownDepression | Quality of Life | Sleep | Anxiety | Dry EyeCanada
-
U.S. Wound RegistryRecruitingWounds and Injuries | Diabetic Foot | Leg Ulcer | Skin Ulcer | Diabetes Complications | Diabetic Neuropathies | Lymphedema | Peripheral Arterial Disease | Vasculitis | Venous Insufficiency | Varicose Ulcer | Pressure Ulcer | Pyoderma | Surgical Wound Dehiscence | Amputation StumpUnited States
-
University Hospital, MontpellierCompletedOsteoarthritis | Mindfulness | MBSRFrance
-
Gachon University Gil Oriental Medical HospitalKorea Health Industry Development InstituteCompletedKnee Replacement | AcupunctureKorea, Republic of